VivoSeq
Dermatology

Epidermolysis Bullosa Simplex

6

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Epidermolysis Bullosa Simplex is an early-stage landscape with 6 programs across 5 companies. The most active players are Castle Creek Pharmaceuticals, LLC, Vitae Pharmaceuticals Inc., an Allergan affiliate, ANS Pharma. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Castle Creek Pharmaceuticals, LLC

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2A

ANS Pharma

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 3T

TWi Biotechnology, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Unknown status4 · 50%
Completed2 · 25%
Recruiting1 · 13%
Terminated1 · 13%

Clinical Trials

Trial Activity

8 trials

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
Recruiting·BBioMendics, LLC·Phase 2·NCT07027345·40 enrolled
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Completed·CCastle Creek Pharmaceuticals, LLC·Phase 2·NCT03389308·51 enrolled
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex
Completed·BBioMendics, LLC·Phase 1·NCT05062070·6 enrolled
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
Terminated·CCastle Creek Pharmaceuticals, LLC·Phase 2·NCT03154333·54 enrolled
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex
Unknown status·UUniversity Hospital, Toulouse·Phase 2/3·NCT03453632·25 enrolled
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Unknown status·—·Phase 3·NCT01340235·8 enrolled
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
Unknown status·UUppsala University·Phase 2·NCT00936533·40 enrolled
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT02470689·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)